Disconnected workflow
Diagnosis and treatment often occur in separate steps, across different settings and timelines.
Early-stage medtech
Advancing skin cancer care through integrated diagnosis and treatment
EpiMass is developing an innovation intended to enable seamless diagnosis and treatment of skin cancer in a single procedure — reducing fragmentation in clinical workflows and supporting earlier, more decisive care.
Try surgery with EpiMass!
Hover to classify tissue. Click, hold, and drag to ablate the tumor only.
Live spectral readout
Classification
Background
No tissue detected
Illustration for demonstration purposes only. Not representative of validated clinical data
Unmet need
Skin cancer care remains fragmented across diagnosis and treatment
For many patients, the path from suspicion to confirmed diagnosis and appropriate treatment involves multiple appointments, delays, and handoffs between specialties. This fragmentation can prolong uncertainty, increase healthcare burden, and complicate timely intervention.
Prolonged uncertainty
Patients may wait between biopsy, histopathology, and treatment planning — a period of significant anxiety.
System-level burden
Repeated visits and fragmented pathways place additional demand on clinicians and healthcare systems.
EpiMass is being developed to address these workflow gaps. Clinical validation is planned as part of the development pathway.
The EpiMass approach
An integrated concept for diagnosis and treatment in one procedure
EpiMass is developing a technology intended to support clinicians in evaluating suspicious lesions and proceeding toward treatment within a more unified clinical workflow. The approach is designed with the goal of reducing procedural fragmentation while maintaining rigorous clinical standards.
Workflow integration
Designed to bring diagnostic evaluation and treatment planning closer together within a single clinical encounter.
Clinician-centered design
Developed with input from clinical practice needs, prioritizing usability within existing dermatological workflows.
Evidence-driven development
Progressing through structured pre-clinical and clinical evaluation to generate supporting evidence.
Concept diagram placeholder
Technical schematic and workflow diagram to be inserted.
EpiMass is in early development. The described capabilities represent development objectives and are subject to clinical validation and regulatory review.
Development stage
Building toward clinical validation
EpiMass is in early development, with clinical implementation and studies now being initiated. Our roadmap reflects a disciplined progression from concept to evidence generation.
Concept & feasibility
CompletedInitial concept development and technical feasibility assessment.
Prototype development
CompletedIterative engineering of device prototypes and core technology validation.
Pre-clinical evaluation
Current stageLaboratory and pre-clinical studies to establish foundational performance data.
Clinical studies
PlannedStructured clinical implementation studies to evaluate safety and performance in practice.
Regulatory pathway
PlannedEngagement with regulatory frameworks aligned with intended market entry.
Clinical implementation
A structured pathway toward clinical evidence
EpiMass is beginning clinical implementation and studies as part of a careful, evidence-oriented development process. Clinical data will be generated progressively and reported as studies advance.
Study design
Defining clinical endpoints, inclusion criteria, and evaluation protocols in collaboration with clinical advisors.
Site engagement
Establishing partnerships with clinical sites and investigators for structured implementation studies.
Evidence generation
Collecting clinical performance and safety data to inform development decisions and regulatory strategy.
Publication & transparency
Sharing validated findings through appropriate scientific and regulatory channels as they become available.
Clinical results and regulatory milestones will be updated here as they are achieved. No clinical outcomes are reported at this stage.
Market relevance
A significant and growing clinical need
Skin cancer represents one of the most prevalent cancer types globally. The demand for more efficient, patient-centered diagnostic and treatment pathways continues to grow alongside incidence rates.
Global prevalence
Skin cancer incidence continues to rise in many regions, placing sustained pressure on dermatology and oncology services.
Workflow inefficiency
Current multi-step pathways create bottlenecks that affect both patient experience and healthcare resource utilization.
Innovation opportunity
Integrated approaches that streamline diagnosis-to-treatment workflows represent a meaningful area for medtech innovation.
Specific market sizing and commercial projections will be added as the company advances its business development activities.
Team
Experienced leadership building toward clinical impact
EpiMass is led by a team with expertise spanning medtech development, clinical practice, and commercial strategy. Full team profiles will be published as the organization grows.
Founder Name
Co-founder & CEO
Background in medtech innovation and clinical translation. Leading EpiMass strategy and development.
LinkedIn profile placeholder
Founder Name
Co-founder & CTO
Expertise in device engineering and technology development. Driving core product architecture.
LinkedIn profile placeholder
Advisor Name
Clinical Advisor
Dermatology and skin cancer specialist providing clinical guidance on development and study design.
LinkedIn profile placeholder
Advisor Name
Regulatory Advisor
Experience in medical device regulatory pathways across European and international markets.
LinkedIn profile placeholder
Vision
Redefining the standard of care in skin cancer
“We envision a future where the path from suspicion to treatment is seamless — where patients receive clarity and care without unnecessary delay, and clinicians are equipped with integrated tools that support confident decision-making.”
EpiMass aims to contribute to this future through rigorous development, clinical evidence, and collaboration with healthcare partners, investors, and the broader medtech ecosystem.
FAQ
Frequently asked questions
EpiMass is in early development. The company has progressed through initial concept and prototype stages and is now initiating pre-clinical evaluation and clinical implementation studies.
Clinical validation is underway as part of our structured development pathway. No clinical outcomes are reported publicly at this stage. Results will be shared as studies progress and data become available.
EpiMass is engaging with regulatory frameworks appropriate to its intended classification and markets. Specific regulatory milestones and submissions will be communicated as the pathway advances.
We welcome engagement from clinical investigators, healthcare institutions, strategic partners, and investors who share our commitment to advancing skin cancer care through evidence-based innovation.
No. EpiMass is not commercially available and is not approved for clinical use. The technology is in development and subject to clinical evaluation and regulatory review.
Please reach out via the email address in our contact section or footer. We respond to inquiries from investors, clinical partners, and collaborators.
Contact
Let's advance skin cancer care together
Whether you are an investor, clinical partner, or collaborator, we welcome the opportunity to discuss how EpiMass can contribute to better patient outcomes.
Get in touch at
contact@epimass.com